A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
Status:
Recruiting
Trial end date:
2023-05-04
Target enrollment:
Participant gender:
Summary
This trial will be conducted to evaluate the efficacy and safety of the Centanafadine
extended release (XR) capsules in adolescent subjects (13 - 17 years, inclusive) with ADHD.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.